Azenta (AZTA) Investor Day 2025 summary

Strategic Direction and Business Transformation

• Transitioned to a decentralized operating model, empowering general managers with P&L accountability and regional commercial leaders to drive performance closer to customers.

• Prioritized operational excellence by embedding the Azenta Business System to drive lean manufacturing, back-office efficiency, and reinvestment in R&D, sales, and marketing.

• Redirected resources from G&A to high-growth areas, focusing on high-margin, recurring revenue streams and clear product roadmaps.

• Enhanced commercial execution through regionalized sales teams, sales bundling, downstream marketing, and price optimization initiatives.

• Disciplined capital allocation strategy with four levers: productivity/gross margin improvement, organic growth, M&A, and share buybacks, including a $250 million repurchase program.

Growth Initiatives and Market Positioning

• Scaling biorepositories geographically and by product, targeting 100 million samples stored by 2030, up from 60 million today.

• Regionalizing Gene Synthesis with investments in U.S. and Western Europe to meet local demand and improve delivery speed.

• Investing in automation and digital transformation, including modular, scalable storage solutions and e-commerce platforms to enhance customer experience.

• Multiomics business leverages a one-stop shop model for sequencing and synthesis, with over 70% recurring revenue and a broad, sticky customer base.

• Addressable markets for SRS/SMS and Multiomics are each ~$3 billion, with current shares of 11% and less than 10%, respectively, providing significant runway for growth.

Operational Excellence and Performance

• Implementing the Azenta Business System (ABS) to improve quality, delivery, and cost efficiency, with early successes including a 55% reduction in store complaints and 30% improvement in on-time delivery.

• Go-to-market approach revamped with regional sales models, sales bundling, and value-based pricing to deepen customer relationships.

• Recurring revenue represents ~55% of total, with a deep installed base and high customer retention, especially among top pharma/biotech clients.

• Leadership and board bring deep expertise, supporting a high-performance culture and strategic execution.

• Both business segments benefit from strong market tailwinds, differentiated end-to-end solutions, and ongoing investments in digital and automation capabilities.